SCYX logo

SCYNEXIS, Inc.

SCYX
Healthcare|Medical - Pharmaceuticals|US
$3.50
+0.20 (+6.06%)
Tangible Book / Share
$4.99
Cash / Share
$3.98
Next Earnings Report
Mar 3, 2027
EPS est. -$0.68 · Revenue est. $135.5K
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Nov 5, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (0)

No upcoming completion dates found in active trials.

Recent Press Releases

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Nov 5, 2026 · GlobeNewsWire
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
Oct 29, 2026 · GlobeNewsWire
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
Oct 22, 2026 · GlobeNewsWire
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
Oct 21, 2026 · GlobeNewsWire
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Oct 6, 2026 · GlobeNewsWire
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Sep 28, 2026 · GlobeNewsWire
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
Sep 22, 2026 · GlobeNewsWire
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Sep 15, 2026 · GlobeNewsWire
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Sep 10, 2026 · GlobeNewsWire
SCYNEXIS to Participate in Upcoming Investor Conferences
Sep 1, 2026 · GlobeNewsWire

SEC Filings (53)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026S-3Shelf registrationDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Sep 28, 20268-KMaterial eventDocumentIndex
Sep 22, 20268-KMaterial eventDocumentIndex
Sep 10, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 10, 2026S-8Employee stock planDocumentIndex
Aug 10, 202610-QQuarterly reportDocumentIndex
Jul 20, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 26, 20268-KMaterial eventDocumentIndex
May 29, 20268-KMaterial eventDocumentIndex
May 22, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 11, 202610-QQuarterly reportDocumentIndex
May 8, 2026EFFECTDocumentIndex
May 8, 2026424B3Offering prospectusDocumentIndex
May 1, 2026S-3Shelf registrationDocumentIndex
Apr 30, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 30, 2026ARSAnnual report to holdersDocumentIndex
Apr 30, 2026DEFA14AProxy / shareholder voteDocumentIndex
Apr 28, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 27, 2026DEF 14AProxy / shareholder voteDocumentIndex
Apr 20, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 20, 20268-KMaterial eventDocumentIndex
Apr 17, 2026PRE 14AProxy / shareholder voteDocumentIndex
Apr 8, 2026SC 13GPassive 5%+ stakeDocumentIndex
Apr 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 31, 20268-KMaterial eventDocumentIndex
Mar 4, 202610-KAnnual reportDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 14, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 12, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 5, 202510-QQuarterly reportDocumentIndex